Choosing the Right ANA Test: When to Order IFA, ELISA/EIA, or LIA/ANA Profile
IIFA on HEp-2 cells remains the reference standard for initial ANA screening and should be your first-line test when evaluating for systemic autoimmune diseases, as it provides the highest sensitivity (>95% in SLE) and critical pattern information that guides subsequent testing 1.
Testing Sequence Algorithm
First-Line Screening
- Order ANA by IIFA (HEp-2 cells) for initial screening when clinical suspicion for systemic autoimmune disease exists
- Screen at 1:160 dilution for adults (represents the 95th percentile in healthy controls) 1
- IIFA detects the broadest range of autoantibodies including those not captured by solid-phase assays 1
When to Use Alternative Methods
ELISA/EIA as Initial Screen:
- High-throughput laboratories requiring automation and rapid turnaround 1
- Better sensitivity for specific diseases like SLE and systemic sclerosis (90-97% vs 80% for IFA in some studies) 2
- Critical limitation: Lower specificity (36-94%) compared to IIFA (99%) 2
- Must confirm positive ELISA results with IIFA to determine titer and pattern 2
LIA/ANA Profile:
- Not for initial screening - use only after positive ANA screen 3
- Best for identifying specific antigen subspecificities (Sm D, RNP 70kD, Ro52/Ro60) 3
- Higher specificity than ELISA for anti-Sm (when Sm D detected), anti-RNP (when 70kD detected), and anti-SSA/Ro (when Ro60 detected) 3
- Particularly useful when IIFA pattern suggests specific antibodies requiring confirmation
Practical Advantages and Limitations
IIFA (HEp-2 cells)
Advantages:
- Detects antibodies to >100 different antigens 1
- Pattern recognition guides reflex testing (homogeneous → anti-dsDNA; nucleolar → anti-Scl70, RNA polymerase; centromere → anti-CENP) 1
- Highest specificity (99%) 2
- Detects cytoplasmic patterns (anti-Jo-1, ribosomal P) missed by many solid-phase assays 1
Limitations:
- Labor-intensive, requires highly trained technicians 1
- Subjective interpretation variability 4
- Up to 25% false positives in healthy populations at low dilutions 1
- Time-consuming for high-volume laboratories 1
ELISA/EIA
Advantages:
- Automated, objective, high-throughput 1
- Quantitative results 5
- Better sensitivity in low pre-test probability populations 6
- Cost-effective for initial screening 2
Limitations:
- Limited antigen panel (typically 6-12 antigens) 1
- Cannot detect pattern information 1
- Results should not be called "ANA test" or "ANA screen" - specify method used 1
- Misses rare but clinically important antibodies 1
LIA/ANA Profile
Advantages:
- Detects antigen subspecificities (Sm B/B' and D; RNP 70kD, A, C; Ro52 and Ro60) 3
- Higher specificity than ELISA for certain antibodies 3
- Good correlation for anti-CENP-B and anti-Jo-1 3
Limitations:
- Lower sensitivity than ELISA for some antibodies (particularly anti-RNP) 3
- Not suitable for initial screening 3
- More expensive than standard ELISA 3
Ideal Testing Sequence
Standard Approach:
- IIFA at 1:160 → If positive, report titer and pattern
- Reflex to specific antibody testing based on pattern and clinical context 1
- Homogeneous → anti-dsDNA, anti-histone
- Speckled → anti-ENA panel (Sm, RNP, SSA/Ro, SSB/La, Scl-70)
- Centromere → anti-CENP-B
- Nucleolar → anti-Scl-70, RNA polymerase III
High-Volume Laboratory Alternative:
- ELISA/EIA screen → If positive
- Confirm with IIFA to determine titer and pattern 2
- LIA for antigen subspecificities if clinically indicated
Critical Pitfalls to Avoid
- Never skip IIFA confirmation of positive solid-phase assays - you will miss pattern information essential for diagnosis 1
- Do not refuse specific antibody testing (anti-Jo-1, ribosomal P, SSA/Ro) based on negative ANA screen in high clinical suspicion cases - these can be ANA-negative by IIFA 1
- Always specify the method used on laboratory reports - clinicians often assume IIFA characteristics apply to all methods 1
- Report each method's results separately when multiple platforms are used 1
- In low pre-test probability populations, solid-phase assays may be more appropriate to reduce false positives 6
The 2014 international consensus emphasizes that IIFA remains the reference method while acknowledging that automated methods have a role in modern laboratories, provided their limitations are clearly communicated 1. The key is matching the test to your laboratory's capabilities and patient population while ensuring appropriate confirmatory testing.